Chlorprothixene


Concise Prescribing Info
Indications/Uses
Psychoses.
Dosage/Direction for Use
Adult: PO 15-50 mg 3-4 times/day, up to ≥600 mg/day in severe conditions. IM 25-100 mg up to 4 times/day.
Administration
May be taken with or without food. Take w/ meals or milk if GI upset occurs.
Contraindications
Coma; CNS depression; pheochromocytoma.
Special Precautions
Hepatic or renal impairment; history of jaundice; CV disease; angle-closure glaucoma; diabetes mellitus; hyperthyroidism; Parkinson's disease; epilepsy, depression, myasthenia gravis; prostatic hypertrophy; severe respiratory disease; blood dyscrasias. May precipitate coma, affect driving; elderly and children. Pregnancy and lactation
Adverse Reactions
Dry mouth, constipation, urinary retention, mydriasis; agitation, insomnia, depression, convulsions, nasal congestion, tachycardia, postural hypotension, blurred vision, inhibition of ejaculation; urticaria, exfoliative dermatitis; agranulocytosis; extrapyramidal dysfunction; altered endocrine and metabolic functions.
Drug Interactions
ACE inhibitors, α-blockers, amantadine, general anaesthetics, angiotensin-II receptor antagonists, antiarrhythmics, tricyclic antidepressants, anxiolytics and hypnotics, apomorphine, artemether with lumefantrine, barbiturates, bromocriptine, cabergoline, calcium-channel blockers, carbamazepine, cimetidine, ethosuximide, levodopa, lisuride, memantine, methyldopa, metoclopramide, opioid analgesics, oxcarbazepine, pergolide, phenytoin, pramipexole, primidone, ritonavir, ropinirole, sibutramine, sympathomimetics, terfenadine, tetrabenazine, tramadol and valproate. Alcohol.
CIMS Class
ATC Classification
N05AF03 - chlorprothixene ; Belongs to the class of thioxanthene derivatives antipsychotics.
Disclaimer: This information is independently developed by CIMS based on chlorprothixene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in